Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Introducing in the U.S. the Alcyon 300 and 300i bench-top clinical chemistry analyzers for routine and special chemistry testing at labs running fewer than 1,000 tests per day or 100,000 tests annually. Both analyzers received 510(k) clearance in February and offer a "49-assay menu of liquid reagents, an automated cuvette handler, 39 sample holders, 24 reagent positions and the ability to process up to 300 photometric tests per hour," the firm says. The initial menu of assays is expected to increase to 60 "within a year," while another 30 assays are under development, Abbott notes. The 300i offers an integrated ISE (chloride, potassium, sodium) module. The systems are based on technology developed by French manufacturer Alcyon Analyzer, which Abbott acquired in 1997 ("The Gray Sheet" Feb. 10, In Brief)

You may also be interested in...

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts